Skip to main content
    M

    MiMedx Group Inc (MDXG)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.18
    +0.00 (+0.00%)

    Market Cap: $464.04M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    MiMedx Group Inc (MDXG) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    MiMedx Group (MDXG) has a market cap of $464.04M and an enterprise value of $343.25M. Revenue fell 22.80% over the last 12 months from the 12 months before. It holds $120.79M more cash than debt, 26.03% of its market cap.

    Total Valuation

    Enterprise value is 26.03% below the market cap, as cash exceeds debt.

    Market Cap$464.04M
    Enterprise Value$343.25M
    Latest price (Nov 17, 2026)$3.18

    Key Dates

    The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 23, 2027 (expected)
    Last Earnings DateOct 28, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 1.31% in the quarter ended Sep 30, 2026 and shrank 0.37% a year over 2 years.

    Shares Outstanding145.87M
    Shares Change (YoY)-1.47%
    Shares Change (QoQ)-1.31%
    Share Count Growth (2Y CAGR)-0.37%

    Valuation Ratios

    Sales and book value multiples are 1.5x and 2.2x. Its year-end P/E ranged from 15.4x to 100.9x from 2016 to 2025.

    P/E Ratio106.0x
    P/S Ratio1.5x
    Forward P/S1.8x
    P/B Ratio2.2x
    P/TBV Ratio2.6x
    P/FCF Ratio24.3x
    P/OCF Ratio22.4x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 17.9x free cash flow.

    EV / Sales1.1x
    EV / FCF17.9x

    Price Statistics

    The stock is down 56.91% over 52 weeks and trades 24.29% below its 50-day average.

    Beta (1Y)0.56
    52-Week Change-56.91%
    1-Month Change-27.40%
    3-Month Change-28.54%
    6-Month Change-12.64%
    5-Year Change-43.36%
    10-Year Change-56.45%
    Total Return (1Y)-56.91%
    Total Return (3Y CAGR)-23.34%
    Total Return (5Y CAGR)-16.07%
    Return vs SPY (1Y)-64.24%
    Max Drawdown (1Y)-57.45%
    Max Drawdown (3Y)-68.36%
    Sharpe Ratio (1Y)-1.73
    Correlation with SPY (1Y)0.18
    50-Day Average$4.20
    200-Day Average$4.15
    52-Week Range$3.03 to $7.45
    RSI (14 Days)25.2
    Average Volume (20 Days)1.76M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.35x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio4.35x
    Quick Ratio3.84x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -9.09% and return on assets is -7.26% over the last 12 months.

    Return on Equity (ROE)-9.09%
    Return on Assets (ROA)-7.26%
    ROA (5Y Average)6.30%
    ROIC (5Y Average)18.80%
    Asset Turnover1.04x
    Inventory Turnover3.21x
    Receivables Turnover7.73x
    Cash Conversion Cycle108 days

    Scores

    MDXG has an Altman Z-Score of 6.28, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score6.28
    Altman Z ZoneSafe
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $303.73M over the last 12 months.

    Revenue$303.73M
    Revenue Growth (YoY)-22.80%
    Gross Profit$234.75M
    Operating Income-$25.14M
    Pretax Income-$22.38M
    Net Income-$19.19M
    EBITDA-$17.90M
    Reported EPS (TTM)$0.03

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 79.79% of the $264.55M in total assets.

    Cash and Equivalents$120.79M
    Total Debt$0
    Net Cash$120.79M
    Net Cash Per Share$0.83
    Working Capital$144.20M
    Shareholder Equity$211.08M
    Book Value Per Share$1.45
    Tangible Book Value$180.52M
    Tangible Book Per Share$1.24
    Total Assets$264.55M
    Total Liabilities$53.47M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.62M of capital spending, operating cash flow left $19.12M of free cash flow.

    Operating Cash Flow$20.74M
    Capital Expenditures$1.62M
    Free Cash Flow$19.12M
    FCF Per Share$0.13
    Depreciation and Amortization$7.83M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -8.28%, against a 5-year average of 7.05%.

    Gross Margin77.29%
    Operating Margin-8.28%
    Pretax Margin-7.37%
    Net Margin-6.32%
    EBITDA Margin-5.89%
    FCF Margin6.30%
    Gross Margin (5Y Average)82.79%
    Operating Margin (5Y Average)7.05%
    Net Margin (5Y Average)5.27%

    Growth

    Revenue grew 16.05% a year over 3 years.

    Revenue Growth (3Y CAGR)+16.05%
    Revenue Growth (5Y CAGR)+11.02%
    EPS Growth (5Y CAGR)+37.35%
    Book Value Per Share Growth (2Y CAGR)+33.33%
    Tangible Book Per Share Growth (2Y CAGR)+36.69%

    Revenue and profit by year

    Dividends and Yields

    MDXG does not pay a dividend. Its free cash flow yield is 4.12%.

    Earnings Yield0.94%
    FCF Yield4.12%
    Buyback Yield0.07%
    Shareholder Yield0.07%

    Stock Splits

    The last reverse split was on Apr 2, 2008.

    Last Split DateApr 2, 2008
    Split TypeReverse split

    Peer Position

    Against 8 similar companies, MDXG has the 8th highest P/S.

    P/S Ratio1.5x vs 4.7x median
    Revenue Growth (Trailing 4 Quarters, YoY)-22.80% vs +1.89% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -17.26% and EPS growth at -50.76% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-17.26%
    EPS Growth Forecast (2Y CAGR)-50.76%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About MDXG

    What is MDXG's market cap?

    MiMedx Group has a market cap of $464.04M. Its enterprise value, which adds debt and subtracts cash, is $343.25M.

    What is MDXG's P/E ratio?

    MiMedx Group has a trailing P/E ratio of 106.0x.

    How many shares of MDXG are outstanding?

    MiMedx Group has 145.87M shares outstanding. The count is down 1.47% from a year earlier.

    Does MDXG pay a dividend?

    No. MiMedx Group does not pay a dividend.

    How much debt does MDXG have?

    MiMedx Group has $0 of total debt and $120.79M of cash and equivalents, a net cash position of $120.79M.